Sugi Predict

Sugi Predict / Targets / CACNA1H

CACNA1H

Voltage-dependent T-type calcium channel subunit alpha-1H · O95180 · CACNA1H on Sugi Atlas →

50,619 patent compounds predicted against CACNA1H, 23,027 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL116362 SCHEMBL116362 0.45 11/20
Mibefradil Mibefradil (SCHEMBL39551) 1.00 10/20
Mibefradil Mibefradil (SCHEMBL120810) 0.99 10/20
Mibefradil Mibefradil (SCHEMBL678437) 0.97 10/20
SCHEMBL642279 SCHEMBL642279 0.41 10/20
SCHEMBL78090 SCHEMBL78090 0.58 8/20
SCHEMBL145713 SCHEMBL145713 1.00 7/20
SCHEMBL145714 SCHEMBL145714 1.00 7/20
SCHEMBL13399 SCHEMBL13399 0.44 7/20
SCHEMBL619154 SCHEMBL619154 0.41 7/20
SCHEMBL620978 SCHEMBL620978 0.40 7/20
SCHEMBL621013 SCHEMBL621013 0.40 7/20
SCHEMBL429257 SCHEMBL429257 0.50 6/20
SCHEMBL621555 SCHEMBL621555 0.39 6/20
SCHEMBL617973 SCHEMBL617973 0.38 6/20
SCHEMBL476289 SCHEMBL476289 0.65 5/20
SCHEMBL476401 SCHEMBL476401 0.65 5/20
Succedaneaflavanone Succedaneaflavanone (SCHEMBL615879) 0.65 5/20
SCHEMBL564110 SCHEMBL564110 0.61 5/20
SCHEMBL617168 SCHEMBL617168 0.59 5/20

Clinical trials — most relevant to CACNA1H by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination PHASE4UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine. PHASE3COMPLETED
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy PHASE3COMPLETED
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome PHASE1/PHASE2NOT_YET_RECRUITING
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients PHASE2WITHDRAWN
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain PHASE2COMPLETED
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. PHASE2NOT_YET_RECRUITING
Physiologic Effects of Topiramate on Cognition PHASE1COMPLETED
Evaluation of A Clinical Diagnostic Test for CRDS nanRECRUITING
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED
International CRDS Registry nanRECRUITING
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
Role of Calcium Channels in Vascular Function nanCOMPLETED
The Prevalence of RYR1-related Disease nanNOT_YET_RECRUITING
The Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Verapamil in Supraclavicular Brachial Plexus Block nanUNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors nanUNKNOWN
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias nanRECRUITING
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia nanCOMPLETED
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
iCorMicA - Stratified Medicine in Angina nanRECRUITING
High Density Mapping in Brugada Syndrome nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNA1H binder may also engage these)

ProteinNameSimilarity
CACNA1G Voltage-dependent T-type calcium channel subunit alpha-1G 1.000 landscape →
CACNA1I Voltage-dependent T-type calcium channel subunit alpha-1I 1.000 landscape →
Q9EQ60 — 1.000 Q9EQ60 →
Q9Z0Y8 — 1.000 Q9Z0Y8 →
O54898 — 1.000 O54898 →
O88427 — 1.000 O88427 →
Q05152 — 0.996 Q05152 →
P15389 — 0.996 P15389 →
P54282 — 0.995 P54282 →
P97445 — 0.994 P97445 →
SCN5A Sodium channel protein type 5 subunit alpha 0.993 landscape →
Q9JJV9 — 0.993 Q9JJV9 →
CACNA1B Voltage-dependent N-type calcium channel subunit alpha-1B 0.993 landscape →
Q9TUI4 — 0.992 Q9TUI4 →
Q62968 — 0.992 Q62968 →
Q6QIY3 — 0.992 Q6QIY3 →
P19024 — 0.992 P19024 →
SCN10A Sodium channel protein type 10 subunit alpha 0.991 landscape →
P50638 — 0.991 P50638 →
Q02294 — 0.991 Q02294 →
Q9JIS7 — 0.990 Q9JIS7 →
Q61290 — 0.990 Q61290 →
Q07652 — 0.990 Q07652 →
O55017 — 0.990 O55017 →
KCNH3 Voltage-gated inwardly rectifying potassium channel KCNH3 0.989 landscape →
O89047 — 0.989 O89047 →
P27732 — 0.989 P27732 →
KCNA5 Potassium voltage-gated channel subfamily A member 5 0.989 landscape →
CACNA1F Voltage-dependent L-type calcium channel subu 0.989 landscape →
Q61762 — 0.989 Q61762 →